TOday’s Movers: Loxo Oncology (NASDAQ:LOXO) Stock Rating Reaffirmed by Stifel; $190 Target Price Indicates 14.41 % Potential

May 17, 2018 - By Christine Ryals

Loxo Oncology, Inc. (NASDAQ:LOXO) Logo

Investors sentiment decreased to 0.97 in Q4 2017. Its down 0.76, from 1.73 in 2017Q3. It is negative, as 29 investors sold Loxo Oncology, Inc. shares while 43 reduced holdings. 23 funds opened positions while 47 raised stakes. 124.82 million shares or 329.48% more from 29.06 million shares in 2017Q3 were reported.

Manufacturers Life Ins The stated it has 17,589 shares or 0% of all its holdings. Virtu Lc accumulated 10,109 shares. Guggenheim Limited Liability Co invested 0.01% in Loxo Oncology, Inc. (NASDAQ:LOXO). Lord Abbett & Limited Liability Com reported 0.13% in Loxo Oncology, Inc. (NASDAQ:LOXO). Wells Fargo Mn holds 15,710 shares or 0% of its portfolio. 4,386 are held by Bvf Incorporated Il. Royal Financial Bank Of Canada has invested 0% in Loxo Oncology, Inc. (NASDAQ:LOXO). Schwab Charles Mgmt has 108,015 shares for 0.01% of their portfolio. Great West Life Assurance Communication Can invested in 0% or 2,958 shares. Bnp Paribas Arbitrage Sa has 4,787 shares. Barclays Public Ltd invested in 0% or 5,773 shares. Pinnacle Assocs Limited invested in 5,360 shares. Sg Americas Secs Lc owns 1,401 shares. Amer Int reported 15,398 shares stake. State Of Wisconsin Invest Board invested in 22,400 shares or 0.01% of the stock.

Since December 8, 2017, it had 0 insider purchases, and 22 insider sales for $74.63 million activity. Naider Avi Z. sold $1.50 million worth of stock or 15,000 shares. 15,000 shares were sold by Bilenker Joshua H., worth $1.45 million. $141,554 worth of Loxo Oncology, Inc. (NASDAQ:LOXO) shares were sold by Burstein Jennifer. Bonita David P had sold 250,000 shares worth $20.63 million. Another trade for 250,000 shares valued at $20.13M was sold by AISLING CAPITAL III LP. On Friday, December 8 the insider ORBIMED ADVISORS LLC sold $20.63 million.

Loxo Oncology (NASDAQ:LOXO) Rating Reaffirmed

In an analyst note issued on 17 May, The “Buy” rating of Loxo Oncology (NASDAQ:LOXO) shares was reaffirmed by Analysts at Stifel, who now has a $190 target on the stock. Stifel’s target indicates a possible upside of 14.41 % from the stock close price of the company.

Loxo Oncology, Inc. (NASDAQ:LOXO) Ratings Coverage

Among 6 analysts covering Loxo Oncology (NASDAQ:LOXO), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Loxo Oncology has $151 highest and $102.0 lowest target. $126.60’s average target is -23.77% below currents $166.07 stock price. Loxo Oncology had 9 analyst reports since November 28, 2017 according to SRatingsIntel. The rating was maintained by Stifel Nicolaus on Thursday, March 1 with “Buy”. Oppenheimer initiated it with “Buy” rating and $132.0 target in Thursday, February 22 report. As per Monday, April 16, the company rating was upgraded by Morgan Stanley. BTIG Research maintained the shares of LOXO in report on Wednesday, December 20 with “Buy” rating. The rating was maintained by Citigroup on Monday, March 5 with “Buy”. As per Wednesday, May 9, the company rating was maintained by Stifel Nicolaus. Morgan Stanley downgraded the stock to “Equal-Weight” rating in Wednesday, March 21 report.

The stock increased 19.05% or $26.57 during the last trading session, reaching $166.07. About 2.34M shares traded or 476.77% up from the average. Loxo Oncology, Inc. (NASDAQ:LOXO) has risen 146.80% since May 17, 2017 and is uptrending. It has outperformed by 135.25% the S&P500.

Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. The company has market cap of $5.00 billion. The Company’s lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase , which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. It currently has negative earnings. The companyÂ’s preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains.

More notable recent Loxo Oncology, Inc. (NASDAQ:LOXO) news were published by: which released: “Here’s Why Loxo Oncology Rose as Much as 23.3% Today” on May 17, 2018, also with their article: “Loxo Oncology to Announce First Quarter 2018 Financial Results” published on May 01, 2018, published: “5 Biggest Price Target Changes For Thursday” on May 17, 2018. More interesting news about Loxo Oncology, Inc. (NASDAQ:LOXO) were released by: and their article: “Pre-Open Movers 05/17: (WWE) (LOXO) (NTES) Higher; (JNCE) (JCP) (ACXM) Lower (more…)” published on May 17, 2018 as well as‘s news article titled: “Loxo Oncology’s (LOXO) CEO Josh Bilenker on Q1 2018 Results – Earnings Call Transcript” with publication date: May 08, 2018.

Loxo Oncology, Inc. (NASDAQ:LOXO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: